ArticleScientific reports2025
Thioredoxin and tetraspanin 30 (CD63) as potential biomarkers for angioinvasion in papillary thyroid cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Cytokine, Metabolic, and Proliferative Profiling Reveals Divergent Metabolic and Proliferative Responses in Papillary Thyroid Cancer Cells.International journal of molecular sciences · 2026Article
- Inflammation and RONS Dysregulation by Redox Enzymes as Mechanistic Links in HIV-1-Cancer Comorbidity.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Papillary thyroid cancer (PTC) is a heterogeneous malignancy in which current prognostic markers often fail to distinguish between indolent and aggressive disease. The need for reliable biomarkers is especially urgent in cases of angioinvasion, where improved risk stratification could guide decisions such as extended surgery and early radioiodine therapy. This study evaluates thioredoxin (TRX), a redox-regulating protein, and tetraspanin 30 (CD63), a mediator of tumor-endothelial interactions, as potential non-invasive biomarkers of angioinvasive PTC. We analyzed serum samples from 90 patients—45 with histologically confirmed angioinvasion and 45 with low-risk, non-angioinvasive PTC. Both TRX and CD63 levels were significantly elevated in the angioinvasive group (p < 0.001). Logistic regression confirmed their strong association with angioinvasion, and ROC analysis showed high diagnostic performance: TRX (AUC = 0.85), CD63 (AUC = 0.83), and a combined model (AUC = 0.93). These findings support TRX and CD63 as promising biomarkers for detecting angioinvasion and guiding more individualized treatment in PTC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.